Corcept Therapeutics Incorporated
CORTNASDAQHealthcare● Active
$72.62
$-2.27(-3.03%)
Market Cap$7.8B
P/E Ratio—
52W High$91
52W Low$28.66
Corcept Therapeutics Incorporated (CORT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CORT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.30
Est. -$0.14 · -111.3%
Revenue
$0.16B
Est. $0.19B · -11.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CORT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $7.60B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$7.60B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.01 | — | — | — | $0.22B | — |
| ▼ Q2 FY2026 | Apr 30, 2026 | -$0.14 | -$0.30 | -111.3% | $0.16B | $0.19B | -11.0% |
| ▼ Q1 FY2026 | Feb 24, 2026 | $0.33 | $0.20 | -39.4% | $0.20B | $0.25B | -20.7% |
| ▼ Q4 FY2025 | Nov 4, 2025 | $0.18 | $0.16 | -11.1% | $0.21B | $0.26B | -18.7% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $0.23 | $0.29 | +26.1% | $0.19B | $0.24B | -20.5% |
| — Q2 FY2025 | May 5, 2025 | $0.17 | $0.17 | +0.0% | $0.16B | $0.22B | -27.4% |
| ▼ Q1 FY2025 | Feb 26, 2025 | $0.37 | $0.26 | -29.7% | $0.18B | $0.20B | -9.1% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $0.28 | $0.41 | +46.4% | $0.18B | $0.20B | -7.8% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Miss
EPS Actual
-$0.30
EPS Est.
-$0.14
EPS Surpr.
-111.3%
Revenue
$0.16B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
$0.20
EPS Est.
$0.33
EPS Surpr.
-39.4%
Revenue
$0.20B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
$0.16
EPS Est.
$0.18
EPS Surpr.
-11.1%
Revenue
$0.21B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$0.29
EPS Est.
$0.23
EPS Surpr.
+26.1%
Revenue
$0.19B
Q2 FY2025
May 5, 2025
EPS Actual
$0.17
EPS Est.
$0.17
EPS Surpr.
+0.0%
Revenue
$0.16B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
$0.26
EPS Est.
$0.37
EPS Surpr.
-29.7%
Revenue
$0.18B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$0.41
EPS Est.
$0.28
EPS Surpr.
+46.4%
Revenue
$0.18B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $1.15 | $1.27 | $1.32 | 1 |
| Q3 FY2027 | $1.00 | $1.09 | $1.14 | 1 |
| Q2 FY2027 | $0.79 | $0.86 | $0.90 | 1 |
| Q1 FY2027 | $0.46 | $0.50 | $0.53 | 1 |
| Q4 FY2026 | $0.51 | $0.56 | $0.59 | 1 |
| Q3 FY2026 | $0.20 | $0.23 | $0.26 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.4B | $0.5B | $0.5B | 3 |
| Q3 FY2027 | $0.4B | $0.4B | $0.4B | 2 |
| Q2 FY2027 | $0.4B | $0.4B | $0.4B | 2 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 3 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 3 |
| Q3 FY2026 | $0.3B | $0.3B | $0.3B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 30, 2026 | -111.3% | $46.59 | $46.52 | -0.15% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -39.4% | $35.34 | $36.48 | +3.23% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -11.1% | $74.17 | $71.10 | -4.14% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +26.1% | $69.91 | $67.17 | -3.92% |
| ▲ Q2 FY2025 | May 5, 2025 | +0.0% | $72.77 | $73.94 | +1.61% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -29.7% | $61.23 | $63.37 | +3.50% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +46.4% | $48.21 | $46.89 | -2.74% |
| ▲ Q3 FY2024 | Jul 29, 2024 | +39.1% | $35.60 | $36.53 | +2.61% |
Q2 FY2026-0.15%
Report Date
Apr 30, 2026
EPS Beat/Miss
-111.3%
Price Before
$46.59
Price After
$46.52
Q1 FY2026+3.23%
Report Date
Feb 24, 2026
EPS Beat/Miss
-39.4%
Price Before
$35.34
Price After
$36.48
Q4 FY2025-4.14%
Report Date
Nov 4, 2025
EPS Beat/Miss
-11.1%
Price Before
$74.17
Price After
$71.10
Q3 FY2025-3.92%
Report Date
Jul 31, 2025
EPS Beat/Miss
+26.1%
Price Before
$69.91
Price After
$67.17
Q2 FY2025+1.61%
Report Date
May 5, 2025
EPS Beat/Miss
+0.0%
Price Before
$72.77
Price After
$73.94
Q1 FY2025+3.50%
Report Date
Feb 26, 2025
EPS Beat/Miss
-29.7%
Price Before
$61.23
Price After
$63.37
Q4 FY2024-2.74%
Report Date
Oct 30, 2024
EPS Beat/Miss
+46.4%
Price Before
$48.21
Price After
$46.89
Q3 FY2024+2.61%
Report Date
Jul 29, 2024
EPS Beat/Miss
+39.1%
Price Before
$35.60
Price After
$36.53
Avg Beat Reaction-0.61%
Avg Miss Reaction+0.61%
Beat Rate4 / 8 quarters
Largest Move-4.14% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CORT ends December
Corcept Therapeutics Incorporated (CORT) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.30 — missing the analyst consensus of $-0.14 by -111.3%. The next CORT earnings date is expected around September 1, 2026.
Each quarter, investors track CORT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CORT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CORT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CORT earnings · 5 questionsCorcept Therapeutics Incorporated's next earnings report is expected around September 1, 2026. CORT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CORT historically reports after market close (AMC).
CORT earnings datewhen is CORT earningsCORT next earnings datewhen does CORT report earningsCORT earnings calendar
▸ Source: FMP · Corcept Therapeutics Incorporated SEC filings · US GAAP · Corcept Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026